Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG

NCT00061425 Phase 1/Phase 2 COMPLETED

The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.

Details

Lead sponsor	Gilead Sciences
Phase	Phase 1/Phase 2
Status	COMPLETED
Start date	2000-08

Conditions

• Non-Hodgkin's Lymphoma
• Lymphoma, B-Cell

Interventions

• radiolabeled epratuzumab